Stocksigma LogoStocksigma Logo

Kwality Pharmaceuticals Posts Robust Q2FY27 Growth and Appoints B S R & Co

Kwality Pharmaceuticals reported strong Q2FY27 consolidated revenue growth of 63% YoY to ₹181 crore (+11.7% QoQ), with EBITDA margin expanding to 27.5%

Kwality Pharmaceuticals Posts Robust Q2FY27 Growth and Appoints B S R & Co

Kwality Pharmaceuticals Ltd · Change in Auditor · 12 Nov 2026, 6:37 pm

Kwality Pharmaceuticals Posts Robust Q2FY27 Growth and Appoints B S R & Co. Kwality Pharmaceuticals reported strong Q2FY27 consolidated revenue growth of 63% YoY to ₹181 crore (+11.7% QoQ), with EBITDA margin expanding to 27.5% from 23.4% in Q2FY26. Net profit doubled YoY to ₹50 crore as PAT margin reached 16%. Driven by international product registrations, management raised its FY27 revenue guidance to ₹720+ crore from ₹700 crore. Additionally, the company acquired 4 acres in Amritsar for Unit 7, secured Hungary EU-GMP certification, and appointed B S R & Co. LLP as statutory auditors following Vijay Mehra & Co.'s resignation on 12th Nov'26.

Original exchange filing (PDF)

More announcements from Kwality Pharmaceuticals Ltd

All Kwality Pharmaceuticals Ltd announcements